Sanofi In Phase III Trials For Dengue Vaccine, Offering Emerging Market Potential
This article was originally published in PharmAsia News
Sanofi already generates a substantial share of its revenue from emerging markets, but developing the first dengue vaccine would have significant impact on emerging market revenue, perhaps as early as 2015.
You may also be interested in...
Regulators in Southeast Asia are working to tighten bribery and corruption enforcement as part of a broader push ahead of an Association of Southeast Asian Nations trade pact in 2015 for greater transparency in pharmaceuticals.
The first commercial implant for St. Jude’s Allure Quadra in Hong Kong is a sign for optimism for its pacemaker business after last year’s disappointments in Japan.